The purpose of this study is to assess the efficacy of this combination of drugs in light chain (AL) amyloidosis which has relapsed or become refractory to other treatments. Amyloidosis is a rare disease that is caused by a substance called amyloid. Amyloid is an abnormal protein produced by plasma cells in the bone marrow which cannot be broken down by the body and so accumulate over time in various organs. Amyloidosis can affect different organs in different people. The most commonly affected organs are the heart, kidney, liver, spleen, nervous system, and digestive tract.

We are looking for people to participate in a Weill Cornell research study using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) to better understand brain processes that may make Traumatic Brain Injury (TBI) a risk factor for later development of Alzheimer’s Disease or Chronic Traumatic Encephalopathy (CTE).

Research study participation lasts up to two years and involves:

This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.

The primary goal of this study is to assess whether using recent advances in technology to treat high intermediate risk and high-risk prostate cancer (HrPCa) can improve clinical outcomes, measured as recurrence-free survival at 2 years after treatment.

The purpose of the initial (phase I) portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 leads to treatment response.
   

This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? 

This registry trial is to collect information on men and women undergoing a Transjugular Intrahepatic Portosystemic Shunt or TIPS and to evaluate the long-term outcomes and complications over a 5-year period. 

The CIBMTR does research with medical data from patients who have had a transplant or other cellular therapy and donors who donate bone marrow or peripheral blood stem cells (PBSCs). The goal of this research is to find ways to make bone marrow and PBSC transplants and other cellular therapies work better.

The purpose of storing a blood sample from donors and their recipients in the NMDP/CIBMTR Research Sample Repository is to provide cells and plasma (the liquid portion of blood) for the NMDP/CIBMTR Research Sample Repository. By studying the cells and plasma of donors and recipients, researchers may learn more about improving the tissue matching between unrelated donors and their recipients. Increasing knowledge about tissue matching could result in the improved long-term survival of bone marrow and stem cell transplant recipients.

Cord blood (CB) is blood that is taken from the umbilical cord and placenta of healthy newborn babies after childbirth. The cord blood collected from a newborn baby is called a cord blood unit. Cord blood units are stored frozen (cryopreserved) in public cord blood banks. Approximately 10,000 cord blood transplants have been performed in children and adults for blood cancers and other blood diseases in the world.